Joshua Zebadiah Willey

Joshua Zebadiah Willey

Auto-generated profile, based on publicly available information

Joshua Zebadiah Willey

Department of Neurology, Columbia University Medical Center, New York, NY (J.Z.W.).

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in JAMA Neurology
Verified
Journal Article
Closed access
PDF file
SYShadi Yaghi
Shadi Yaghi
AEAndrew Eisenberger
Andrew Eisenberger
JWJoshua Z. Willey
Joshua Z. Willey
Importance Intravenous thrombolysis remains the mainstay treatment for acute ischemic stroke. One of the most feared complications of the treatment is thrombolysis-related symptomatic intracerebral hemorrhage (sICH), which occurs in nearly 6% of patients and carries close to 50% mortality. The treatment options for sICH are based on small case series and expert opinion, and the efficacy of recommended treatments is not well known. Objective To provide an overview on the rationale and mechanism of action of potential treatments for sICH that may reverse the coagulopathy before hematoma expansion occurs. Evidence Review Evidence-based peer-reviewed articles, including randomized trials, case series and reports, and retrospective reviews, were identified in a PubMed search on the mechanism of action of intravenous recombinant tissue plasminogen activator and the rationale of various potential treatments using the coagulation cascade as a model. The search encompassed articles published from January 1, 1990, through February 28, 2014. Findings The current treatments may not be sufficient to reverse coagulopathy early enough to prevent hematoma expansion and improve the outcome of thrombolysis-related hemorrhage. Conclusions and Relevance Given the mechanism of action of intravenous recombinant tissue plasminogen activator, clinical studies could include agents with a fast onset of action, such as prothrombin complex concentrate, recombinant factor VIIa, and ε-aminocaproic acid, as potential therapeutic options.

24 November 2009 in Neurology
Verified
Journal Article
Closed access
PDF file
JWJ. Z. Willey
J. Z. Willey
YMY. P. Moon
Y. P. Moon
MPM. C. Paik
M. C. Paik
BBB. Boden-Albala
B. Boden-Albala
RSR. L. Sacco
R. L. Sacco
MEM.S.V. Elkind
M.S.V. Elkind
Background: It is controversial whether physical activity is protective against first stroke among older persons. We sought to examine whether physical activity, as measured by intensity of exercise and energy expended, is protective against ischemic stroke. Methods: The Northern Manhattan Study is a prospective cohort study in older, urban-dwelling, multiethnic, stroke-free individuals. Baseline measures of leisure-time physical activity were collected via in-person questionnaires. Cox proportional hazards models were constructed to examine whether energy expended and intensity of physical activity were associated with the risk of incident ischemic stroke. Results: Physical inactivity was present in 40.5% of the cohort. Over a median follow-up of 9.1 years, there were 238 incident ischemic strokes. Moderate- to heavy-intensity physical activity was associated with a lower risk of ischemic stroke (adjusted hazard ratio [HR] 0.65, 95% confidence interval [0.44–0.98]). Engaging in any physical activity vs none (adjusted HR 1.16, 95% CI 0.88–1.51) and energy expended in kcal/wk (adjusted HR per 500-unit increase 1.01, 95% CI 0.99–1.03) were not associated with ischemic stroke risk. There was an interaction of sex with intensity of physical activity (p = 0.04), such that moderate to heavy activity was protective against ischemic stroke in men (adjusted HR 0.37, 95% CI 0.18–0.78), but not in women (adjusted HR 0.92, 95% CI 0.57–1.50). Conclusions: Moderate- to heavy-intensity physical activity, but not energy expended, is protective against risk of ischemic stroke independent of other stroke risk factors in men in our cohort. Engaging in moderate to heavy physical activities may be an important component of primary prevention strategies aimed at reducing stroke risk.

16 September 2014 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JWJoshua Z. Willey
Joshua Z. Willey
YMYeseon Park Moon
Yeseon Park Moon
EKEmily Kahn
Emily Kahn
CRCarlos J. Rodriguez
Carlos J. Rodriguez
TRTatjana Rundek
Tatjana Rundek
MEMitchell S. V. Elkind
Mitchell S. V. Elkind
Background: Understanding the population‐level risk factor contribution to disease incidence is critical for effective allocation of resources for prevention. There are little data on the contribution of cardiovascular disease ( CVD ) risk factors in multiethnic elderly populations. Methods and Results: The Northern Manhattan Study (n=3298) is a population‐based prospective cohort study of CVD outcomes in a multiethnic urban population. Multivariable Cox's models were used to calculate hazard ratios, population attributable risk ( PAR ), and 95% confidence intervals ( CI s) for (1) combined vascular event ( VE ) endpoint of stroke/myocardial infarction/vascular death (n=835) and (2) stroke (n=347). The PAR resulting from hypertension ( HTN ) was 24.3% (95% CI , 13.2 to 35.4) for VE and 29.9% (95% CI , 12.5 to 47.4) for stroke; PAR resulting from diabetes was 12.7% (95% CI , 8.2 to 17.2) for VE and 19.5% (95% CI , 12.4 to 26.5) for stroke. The PAR resulting from HTN and diabetes for stroke differed by race‐ethnicity and age ( P for differences <0.05). PAR for stroke reslting from HTN was greater among Hispanics (50.6%; 95% CI , 29.2 to 71.9) than non‐Hispanic whites (2.6%; 95% CI , −33.2 to 38.6) and in those <80 years of age (35.6%; 95% CI , 18.9 to 52.3) than in those ≥80 (−0.3%; 95% CI , −34.2 to 33.6). Similarly, the PAR for stroke resulting from diabetes was 23.6% among those <80 years of age (95% CI , 15.7 to 31.5) and 2.3% among those ≥80 (95% CI , −8.2 to 12.7; P for difference=0.001). The PAR for VE did not differ by age/sex/race‐ethnicity. Conclusions: HTN and diabetes have important effects on the burden of stroke, particularly among those younger than age 80 and Hispanics. Public health campaigns targeted at specific risk factors in specific populations can lead to a greater reduction in CVD .

14 June 2011 in Neurology
Verified
Journal Article
Closed access
PDF file
JWJ.Z. Willey
J.Z. Willey
YMY.P. Moon
Y.P. Moon
MPM.C. Paik
M.C. Paik
MYM. Yoshita
M. Yoshita
CDC. DeCarli
C. DeCarli
CWC.B. Wright
C.B. Wright
Objective: To examine the independent association between physical activity and subclinical cerebrovascular disease as measured by silent brain infarcts (SBI) and white matter hyperintensity volume (WMHV). Methods: The Northern Manhattan Study (NOMAS) is a population-based prospective cohort examining risk factors for incident vascular disease, and a subsample underwent brain MRI. Our primary outcomes were SBI and WMHV. Baseline measures of leisure-time physical activity were collected in person. Physical activity was categorized by quartiles of the metabolic equivalent (MET) score. We used logistic regression models to examine the associations between physical activity and SBI, and linear regression to examine the association with WMHV. Results: There were 1,238 clinically stroke-free participants (mean age 70 ± 9 years) of whom 60% were women, 65% were Hispanic, and 43% reported no physical activity. A total of 197 (16%) participants had SBI. In fully adjusted models, compared to those who did not engage in physical activity, those in the upper quartile of MET scores were almost half as likely to have SBI (adjusted odds ratio 0.6, 95% confidence interval 0.4–0.9). Physical activity was not associated with WMHV. Conclusions: Increased levels of physical activity were associated with a lower risk of SBI but not WMHV. Engaging in moderate to heavy physical activities may be an important component of prevention strategies aimed at reducing subclinical brain infarcts.

1 August 2016 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JWJoshua Z. Willey
Joshua Z. Willey
MGMichael V. Gavalas
Michael V. Gavalas
PTPauline N. Trinh
Pauline N. Trinh
MYMelana Yuzefpolskaya
Melana Yuzefpolskaya
AGA. Reshad Garan
A. Reshad Garan
PCPaolo C. Colombo
Paolo C. Colombo

1 September 2010 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
JWJoshua Z. Willey
Joshua Z. Willey
MEMitchell S. V. Elkind
Mitchell S. V. Elkind
3-Hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase inhibitors, also known as statins, act on the rate-limiting step in the pathway by which HMG-CoA is converted to mevalonate.1 Through their effect on this pathway (Figure), as well as an increase in low-density lipoprotein cholesterol (LDL-C) receptors and uptake, statins reduce the production of cholesterol, thereby modifying dyslipidemia, which is the most common use for this class of medications. Statins reduce other by-products of the mevalonate pathway, including ubiquinone, dolichol, and the isoprenoids farnesyl pyrophosphate and geranylgeranylpyrophosphate. In turn, farnesyl pyrophosphate and geranylgeranylpyrophosphate are necessary for the posttranslational lipid modification (prenylation) of several proteins that are tethered to the cell wall. Among these key membrane proteins are small guanosine triphosphate–binding proteins such as the Rho family of guanosine triphosphatases, which acts on Rho kinase. Rho kinase downregulates the expression of endothelial nitric oxide synthase (eNOS). This and other proteins have important roles in apoptosis, intracellular vesicular transport, cellular proliferation and differentiation, and the expression of additional membrane proteins (including cell adhesion molecules). Treatment with statins reduces prenylation and modifies several of these cellular functions, with the potential for therapeutic benefit in many neurologic diseases.2